The FDA rejected deramiocel after citing serious problems with its pivotal trial, while Medicare coverage for GRAIL’s Galleri test remains contingent on a future agency decision.
The Food and Drug Administration rejected Capricor Therapeutics’ application for deramiocel, an investigational treatment for Duchenne muscular dystrophy, citing problems with the clinical trial evidence submitted to support approval.
In a Complete Response Letter issued Nov. 20, the agency said the Phase 3 HOPE-3 study had serious deficiencies, including unauthorized post-hoc changes to its statistical plan, blinding violations and other protocol violations. The FDA said those issues compromised the reliability of the data, leaving the application short of the evidence required for approval.
A Complete Response Letter means the FDA has not approved an application as submitted. Capricor said it stands behind its clinical program and is reviewing the letter before deciding next steps. Deramiocel remains investigational; the company has not announced how it will respond.
For people with Duchenne, a progressive genetic disease, the decision means deramiocel is not available as an FDA-approved treatment. The agency’s stated objection concerns the trial record: if study design or conduct undermines the data, regulators cannot confidently judge whether reported results reflect a treatment’s effects. The available information does not establish what deramiocel might cost, how insurers would cover it, or what outcomes patients could expect if it were approved.
The rejection does not determine whether the therapy could eventually benefit patients. Any future path depends on Capricor’s response and further FDA review. For now, patients and clinicians must make care decisions without deramiocel as an approved option.
A separate FDA review of GRAIL’s Galleri blood test shows why advisory recommendations, agency decisions and insurance coverage must be kept distinct. An FDA panel recommended the test, but its advice is not final approval. GRAIL is targeting a potential FDA decision in early 2027.
Galleri is designed to detect signals associated with multiple cancers from a blood sample. GRAIL reported more than 56,000 tests in the third quarter of 2026, about 24% above the year-earlier period. That volume shows increasing use, but by itself does not establish whether the test improves health outcomes. The available information does not provide results linking the reported use to better patient outcomes or specify what the test costs patients.
Medicare coverage remains contingent on FDA approval. A favorable panel recommendation does not guarantee that older patients will have coverage, and even approval would not by itself settle insurance terms. The available information does not specify what Galleri would cost Medicare or beneficiaries if coverage is eventually approved.
The two cases present different regulatory questions: the FDA says flaws in deramiocel’s trial prevent approval now, while Galleri remains under review. In both, patient access depends on evidence regulators can assess and on decisions that follow. For patients and physicians, clarity about what is investigational, approved or covered is essential to making informed choices.
No material new FDA decision on an Eli Lilly weight-loss drug was identified in the recent results. They instead refer to Lilly’s April 1, 2026, approval of Foundayo (orforglipron), a separate, earlier development.

